- Conditions
- Advanced Lymphoma, Advanced Malignant Solid Neoplasm, Hematopoietic and Lymphoid Cell Neoplasm, Refractory Lymphoma, Refractory Malignant Solid Neoplasm, Refractory Multiple Myeloma
- Interventions
- PI3K-beta Inhibitor GSK2636771
- Drug
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years and older
- Enrollment
- 24 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2026
- U.S. locations
- 1
- States / cities
- Philadelphia, Pennsylvania
Condition Directory
Lymphoma clinical trials
Directory of U.S. ClinicalTrials.gov public records for Lymphoma. Browse Lymphoma recruiting trials, filter by phase, sponsor, location, or intervention, and open the official ClinicalTrials.gov study record for each result.
By Clinical Trials Finder Guidance last reviewed June 10, 2026 Data synced October 29, 2026 Report an issue
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official matching trials
1119
Shown on this page
12
Current sort
Recently updated
Condition scope
Lymphoma
Additional filters apply within this condition.
The live registry is temporarily unavailable. These stored records may be incomplete or out of date. Check the official record for current status and contact information.
How Lymphoma studies are organized in the registry
Lymphoma records divide between Hodgkin and non-Hodgkin disease, and non-Hodgkin studies usually name the histology directly — diffuse large B-cell (DLBCL), follicular, mantle cell, and others. Subtype abbreviations are the most reliable narrowing terms because they appear in titles and condition fields verbatim.
Terms that often appear in related listings
These describe how studies tend to be titled and grouped on ClinicalTrials.gov — they are search vocabulary, not medical guidance.
Showing 757–768 of 1,119 matching trials for Lymphoma.
Indexed local directory records.
Stored official records
Open in full search- Conditions
- Recurrent Mantle Cell Lymphoma
- Interventions
- Ibrutinib, Laboratory Biomarker Analysis, Palbociclib, Pharmacological Study
- Drug · Other
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years and older
- Enrollment
- 28 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2027
- U.S. locations
- 4
- States / cities
- St Louis, Missouri • New York, New York • Chapel Hill, North Carolina + 1 more
- Conditions
- Ann Arbor Stage I Small Lymphocytic Lymphoma, Ann Arbor Stage II Small Lymphocytic Lymphoma, Chronic Lymphocytic Leukemia, Chronic Lymphocytic Leukemia With Unmutated Immunoglobulin Heavy Chain Variable-Region Gene, Small Lymphocytic Lymphoma, Small Lymphocytic Lymphoma With Unmutated Immunoglobulin Heavy Chain Variable-Region Gene, Stage 0 Chronic Lymphocytic Leukemia, Stage I Chronic Lymphocytic Leukemia, Stage II Chronic Lymphocytic Leukemia
- Interventions
- Biospecimen Collection, Bone Marrow Aspiration, Bone Marrow Biopsy, Computed Tomography, Lenalidomide, Pneumococcal Polyvalent Vaccine
- Procedure · Drug · Biological
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years to 79 Years
- Enrollment
- 49 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2027
- U.S. locations
- 1
- States / cities
- Columbus, Ohio
- Conditions
- Blood Cancer, Leukemia, Lymphoma, Myeloma
- Interventions
- Music Therapy/MT, Therapist-Attention Music Education/TAME Control
- Other
- Lead sponsor
- Memorial Sloan Kettering Cancer Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 60 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2025 – 2026
- U.S. locations
- 7
- States / cities
- Basking Ridge, New Jersey • Middletown, New Jersey • Montvale, New Jersey + 4 more
- Conditions
- Anaplastic Large Cell Lymphoma, Anaplastic Lymphoma Kinase
- Interventions
- Alectinib, Duvelisib
- Drug
- Lead sponsor
- Memorial Sloan Kettering Cancer Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 30 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2031
- U.S. locations
- 7
- States / cities
- Basking Ridge, New Jersey • Middletown, New Jersey • Montvale, New Jersey + 4 more
- Conditions
- B Cell Acute Lymphoblastic Leukemia (B-ALL), B Lineage Lymphoblastic Lymphoma
- Interventions
- Autologous Humanized CD19-Directed Chimeric Antigen Receptor T-Cells (huCART19)
- Biological
- Lead sponsor
- Stephan Grupp MD PhD
- Other
- Eligibility
- 0 Years to 29 Years
- Enrollment
- 115 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2029
- U.S. locations
- 1
- States / cities
- Philadelphia, Pennsylvania
- Conditions
- Acute Lymphoblastic Leukemia, Pediatric, B Cell Lymphoma, Lymphoma
- Interventions
- Autologous CD22 CAR T, Cyclophosphamide, Fludarabine
- Drug
- Lead sponsor
- Kara Lynn Davis
- Other
- Eligibility
- 1 Year to 30 Years
- Enrollment
- 10 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2022
- U.S. locations
- 1
- States / cities
- Stanford, California
- Conditions
- Anaplastic Large Cell Lymphoma, Nodal Peripheral T-Cell Lymphoma With TFH Phenotype, Recurrent Anaplastic Large Cell Lymphoma, Recurrent Angioimmunoblastic T-Cell Lymphoma, Recurrent Enteropathy-Associated T-Cell Lymphoma, Recurrent Follicular Lymphoma, Recurrent Hepatosplenic T-Cell Lymphoma, Recurrent Mature T- Cell and NK-Cell Non-Hodgkin Lymphoma, Recurrent Monomorphic Epitheliotropic Intestinal T-cell Lymphoma, Recurrent Mycosis Fungoides, Recurrent Peripheral T-Cell Lymphoma, Not Otherwise Specified, Refractory Anaplastic Large Cell Lymphoma, Refractory Angioimmunoblastic T-Cell Lymphoma, Refractory Enteropathy-Associated T-Cell Lymphoma, Refractory Follicular Lymphoma, Refractory Hepatosplenic T-Cell Lymphoma, Refractory Mature T-Cell and NK-Cell Non-Hodgkin Lymphoma, Refractory Mycosis Fungoides, Refractory Peripheral T-Cell Lymphoma, Not Otherwise Specified, Subcutaneous Panniculitis-Like T-Cell Lymphoma
- Interventions
- Pembrolizumab, Pralatrexate
- Biological · Drug
- Lead sponsor
- City of Hope Medical Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 13 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2027
- U.S. locations
- 3
- States / cities
- Duarte, California • Atlanta, Georgia • Omaha, Nebraska
- Conditions
- Hodgkin Lymphoma
- Interventions
- Radiation Therapy, Stanford V Chemotherapy
- Radiation · Drug
- Lead sponsor
- St. Jude Children's Research Hospital
- Other
- Eligibility
- Up to 21 Years
- Enrollment
- 88 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2028
- U.S. locations
- 6
- States / cities
- Palo Alto, California • San Diego, California • Peoria, Illinois + 3 more
- Conditions
- Follicular Lymphoma, Low Grade Non-Hodgkin's Lymphoma, Adult
- Interventions
- Epcoritamab, Rituximab
- Drug
- Lead sponsor
- Reid Merryman, MD
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 100 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2030
- U.S. locations
- 6
- States / cities
- Boston, Massachusetts • New York, New York • Rochester, New York + 2 more
- Conditions
- Diffuse Large B-cell Lymphoma
- Interventions
- Epcoritamab, Investigator's Choice Chemotherapy
- Biological · Drug
- Lead sponsor
- Genmab
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 483 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2028
- U.S. locations
- 15
- States / cities
- Indianapolis, Indiana • Lexington, Kentucky • Jackson, Michigan + 10 more
- Conditions
- Blastoid Variant Mantle Cell Lymphoma, Mantle Cell Lymphoma, Pleomorphic Variant Mantle Cell Lymphoma
- Interventions
- Cyclophosphamide, Cytarabine, Dexamethasone, Doxorubicin, Doxorubicin Hydrochloride, Ibrutinib, Laboratory Biomarker Analysis, Methotrexate, Rituximab, Vincristine, Vincristine Sulfate
- Drug · Other · Biological
- Lead sponsor
- M.D. Anderson Cancer Center
- Other
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 131 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2027
- U.S. locations
- 1
- States / cities
- Houston, Texas
About this Lymphoma clinical trials directory page
- What this page lists
- U.S. ClinicalTrials.gov public records that list Lymphoma as a study condition, including recruiting, not yet recruiting, and active not recruiting trials across phase 1, phase 2, and phase 3.
- How to narrow results
- Use the filters above to scope by intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, age, or NCT ID within Lymphoma.
- Where the data comes from
- Records are sourced from the official ClinicalTrials.gov public API. Each result links back to the official study page, which is the source of truth for eligibility, enrollment, and contact information.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, ranking of trials by quality, or AI-generated medical summaries.
Related: all condition pages, browse by drug or therapy, browse by U.S. city, browse by sponsor, or open the full search for Lymphoma.